Výsledky vyhledávání

Abstract P2-16-04: Attitudes of metastatic breast cancer patients towards research biopsies

Autor: Davinia S.E. Seah, SM Scott, S Come, Jessica Sohl, Nu Lin, Zsofia K. Stadler, Julie Najita, Elizabeth S. Frank, M. Garrett, EP Winer, Thomas H. Openshaw, KJ Krag

Publikováno v: Cancer Research. 72:P2-16

Background: In the era of molecularly targeted therapy, developing an understanding of the molecular basis of cancer is a principal or secondary goal of many research studies. For this reason, studies collecting tissue for research purposes are incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2f98ee2e8ba72894a0cf0fa43156ea1
https://doi.org/10.1158/0008-5472.sabcs12-p2-16-04

Zobrazit plný text záznamu

Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer

Autor: Vered Stearns, Judy Garber, Erica L. Mayer, Leif W. Ellisen, HS Rugo, Paul E. Goss, EP Winer, A-R Hartman, Lisa A. Carey, TA Traina, S Come, Dianne M. Finkelstein, MC Liu, Paula D. Ryan, SJ Isakoff, KJ Krag

Publikováno v: Cancer Research. 72:PD09-03

Background: Triple negative breast cancer (TNBC) has a poor prognosis compared to other BC subtypes and lacks identified specific therapeutic targets. TNBC is frequent among BRCA1-associated breast cancer. Platinum chemotherapy has activity in TNBC,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d61c97088b8c276e15fd671bfe063d1
https://doi.org/10.1158/0008-5472.sabcs12-pd09-03

Zobrazit plný text záznamu

Akademický článek

Baseline Screening MRI Uptake and Findings in Women with ≥ 20% Lifetime Risk of Breast Cancer.

Autor: Laws A; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA., Mulvey TM; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Jalbert N; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Dalton S; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.; Department of Interventional Radiology, UMass Memorial Medical Center, Worcester, MA, USA., Kantor O; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA., Harris KA; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Krag KJ; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Walsh EP; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Coopey SB; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA. scoopey@mgh.harvard.edu.

Publikováno v: Annals of surgical oncology [Ann Surg Oncol] 2020 Oct; Vol. 27 (10), pp. 3595-3602. Date of Electronic Publication: 2020 Jul 18.

Zobrazit plný text záznamu

Akademický článek

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Autor: Isakoff SJ; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT. sisakoff@mgh.harvard.edu., Mayer EL; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., He L; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Traina TA; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Carey LA; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Krag KJ; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Rugo HS; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Liu MC; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Stearns V; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Come SE; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Timms KM; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Hartman AR; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Borger DR; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Finkelstein DM; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Garber JE; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Ryan PD; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Winer EP; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Goss PE; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT., Ellisen LW; Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2015 Jun 10; Vol. 33 (17), pp. 1902-9. Date of Electronic Publication: 2015 Apr 06.

Zobrazit plný text záznamu

Akademický článek

Delta-6-desaturase activity and arachidonic acid synthesis are increased in human breast cancer tissue.

Autor: Pender-Cudlip MC; Laboratory for Lipid Medicine and Technology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Krag KJ, Martini D, Yu J, Guidi A, Skinner SS, Zhang Y, Qu X, He C, Xu Y, Qian SY, Kang JX

Publikováno v: Cancer science [Cancer Sci] 2013 Jun; Vol. 104 (6), pp. 760-4. Date of Electronic Publication: 2013 Mar 19.

Zobrazit plný text záznamu

Akademický článek

CT guided percutaneous calcaneoplasty: a case of metastatic intra-articular calcaneus fracture.

Autor: Kamalian S; Division of Interventional Neuroradiology, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA., Hirsch AE, Growney ML, Raskin KA, Yoo AJ, Krag KJ, Hirsch JA

Publikováno v: Journal of neurointerventional surgery [J Neurointerv Surg] 2009 Dec; Vol. 1 (2), pp. 186-8.

Zobrazit plný text záznamu

Akademický článek

Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.

Autor: Matulonis UA; Department of Medical Oncology Dana-Farber Cancer Institute, Boston, MA 02115, USA. ursula_matulonis@dfci.harvard.edu, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2009 Feb; Vol. 112 (2), pp. 394-9. Date of Electronic Publication: 2008 Dec 05.

Zobrazit plný text záznamu

Akademický článek

Predictive factors for long-term survival in patients with advanced ovarian cancer.

Autor: Krag KJ; Division of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts., Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, Klatt M, Andersen J

Publikováno v: Gynecologic oncology [Gynecol Oncol] 1989 Jul; Vol. 34 (1), pp. 88-93.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání